News & Updates

Patient ethnicity, HBV genotype predict functional cure after therapy withdrawal
Patient ethnicity, HBV genotype predict functional cure after therapy withdrawal
06 Feb 2022

The chances of hepatitis B surface antigen (HBsAg) loss after withdrawing nucleo(s)tide analogue (NUC) treatment depend on factors such as patient ethnicity, end-of-treatment antigen levels, and HBV genotype, a new study reports.

Patient ethnicity, HBV genotype predict functional cure after therapy withdrawal
06 Feb 2022
Hepatitis E virus resistant to alcohol-based disinfectants
Hepatitis E virus resistant to alcohol-based disinfectants
06 Feb 2022
Fenofibrate keeps lid on triglyceride in NASH patients receiving ACC inhibitor
Fenofibrate keeps lid on triglyceride in NASH patients receiving ACC inhibitor
13 Jan 2022 byJairia Dela Cruz

For nonalcoholic steatohepatitis (NASH) patients with hypertriglyceridaemia, treatment with fenofibrate helps reduce the increases in triglyceride levels associated with acetyl-coenzyme A carboxylase (ACC) inhibition, as shown in a study.

Fenofibrate keeps lid on triglyceride in NASH patients receiving ACC inhibitor
13 Jan 2022